Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.
about
MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphomaInhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort StudyVariability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes.New targeted therapies for malignant lymphoma based on molecular heterogeneity.There is life in the old dog yet: thymidine kinase as predictive marker in diffuse large B-cell lymphoma.Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma.Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective.Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma
P2860
Q37142412-5CE27433-721A-4EB9-AB9D-9F717698DCE8Q37618835-30E75DA6-CBC0-4E21-8FF0-F20E744BBC28Q37624237-D9B468B5-4122-4B88-BCA0-94739BF9372AQ37636976-EAEBD005-7479-4FF8-A045-70EB5562ADF6Q38787141-F513949B-57F0-49BE-9A79-99EBBAA0EF0FQ39586919-AC422133-9334-4296-A08F-072DD06BF728Q45594363-DD692EFD-60E5-4852-84C0-71FE70EC7BC3Q47130049-BF8E35CD-6FDF-45FB-9FED-8200F5966B80Q50089372-37856EF0-B6A6-4761-B19B-9BC7ECCCDE6BQ52915032-A833CEF0-479C-4B3B-A336-D7B0D55BA83FQ57759564-31DD985C-283A-4CFE-ADD1-C324E6A28097
P2860
Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.
@ast
Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.
@en
type
label
Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.
@ast
Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.
@en
prefLabel
Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.
@ast
Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.
@en
P2093
P2860
P356
P1476
Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.
@en
P2093
Cliona Grant
Kieron Dunleavy
Wyndham H Wilson
P2860
P356
10.1177/2040620712464508
P577
2013-02-01T00:00:00Z